CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential

Theranostics

Volumn 3, Issue 1, 2013, Pages 26-33

  Wald, Ori ^a   Shapira, Oz M ^a   Izhar, Uzi ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Chemokines; Human; Lung; NSCLC

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHEMOKINE RECEPTOR CXCR7; CISPLATIN; PACLITAXEL; PLERIXAFOR; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1;

CANCER STEM CELL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

CHEMOKINES.; HUMAN; LUNG; NSCLC;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINE CXCL12; HUMANS; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; RECEPTORS, CXCR4;

EID: 84883176178     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4922     Document Type: Review

References (81)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
3. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005 Sep 1;172(5):523-9.
4. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011 Feb;12(2):175-80.
5. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012 Mar;18(3):349-51.
6. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007 Sep;132(3 Suppl):29S-55S.
7. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
8. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012 Jul;62(4):220-41.
9. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011 Aug 4;365(5):395-409.
10. Murthy SC, Reznik SI, Ogwudu UC, Farver CF, Arrossi A, Batizy LH, et al. Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung. Ann Thorac Surg 2010 Oct;90(4):1067-74.
11. Hubbard MO, Fu P, Margevicius S, Dowlati A, Linden PA. Five-year survival does not equal cure in non-small cell lung cancer: A Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival. J Thorac Cardiovasc Surg. 2012.
12. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 2012 Apr;13(71):287-97.
13. Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs 2010;70(2):167-79.
14. Kameyama K, Takahashi M, Ohata K, Igai H, Yamashina A, Matsuoka T, et al. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution. J Thorac Cardiovasc Surg 2009 May;137(5):1180-4.
15. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009 Jul;136(1):260-71.
16. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007 Aug;2(8):706-14.
17. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007 Aug;2(8):694-705.
18. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011 Feb;6(2):244-85.
19. Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol 2010 Oct;4(5):397-403.
20. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011 Sep;11(9):597-606. 21. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000 Feb;12(2):121-7.
21. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000 Feb;12(2):121-7.
22. Mantovani A. Chemokines in neoplastic progression. Semin Cancer Biol 2004 Jun;14(3):147-8.
23. Mantovani A, Allavena P, Sozzani S, Vecchi A, Locati M, Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004 Jun;14(3):155-60.
24. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996 Aug 29;382(6594):829-33.
25. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 2011 Apr;11(4):621-30.
26. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006 Sep 4;203(9):2201-13.
27. Zabel BA, Lewen S, Berahovich RD, Jaen JC, Schall TJ. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol Cancer 2011;10:73.
28. Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, Minina S, et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008 Feb 8;132(3):463-73.
29. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003 Sep 18;425(6955):307-11.
30. Boudot A, Kerdivel G, Habauzit D, Eeckhoute J, Le Dily F, Flouriot G, et al. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS One 2011;6(6):e20898.
31. Jacobson O, Weiss ID, Kiesewetter DO, Farber JM, Chen X. PET of tumor CXCR4 expression with 4-18F-T140. J Nucl Med 2010 Nov;51(11):1796-804.
32. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 2011;1:251-62.
33. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001 Mar 1;410(6824):50-6.
34. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007 Oct 28;256(2):137-65.
35. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005 Mar 1;11(5):1835-41.
36. Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004 Aug 5;23(35):5958-67.
37. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004 Nov;6(5):459-69.
38. Liu YL, Yu JM, Song XR, Wang XW, Xing LG, Gao BB. Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther 2006 Oct;5(10):1320-6.
39. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006 Dec;86(12):1221-32.
40. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004 Aug;18(11):1240-2.
41. Scala S, Giuliano P, Ascierto PA, Ierano C, Franco R, Napolitano M, et al. Human melanoma metastases express functional CXCR4. Clin Cancer Res 2006 Apr 15;12(8):2427-33.
42. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004 Apr;15(4):613-7.
43. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 2005 Dec 1;11(23):8273-80.
44. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 2009 Mar;137(3):615-21.
45. Chen G, Wang Z, Liu XY, Liu FY. High-level CXCR4 expression correlates with brain-specific metastasis of non-small cell lung cancer. World J Surg 2011 Jan;35(1):56-61.
46. Franco R, Pirozzi G, Scala S, Cantile M, Scognamiglio G, Camerlingo R, et al. CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg 2011 Feb;41(2):368-75.
47. Oonakahara K, Matsuyama W, Higashimoto I, Kawabata M, Arimura K, Osame M. Stromal-derived factor-1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol 2004 May;30(5):671-7.
48. Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D, et al. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol 2011 Jul;6(7):1169-78.
49. Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol 2006 Nov 15;177(10):6983-90.
50. Wald O, Izhar U, Amir G, Kirshberg S, Shlomai Z, Zamir G, et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg 2011 Jun;141(6):1503-12.
51. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 2007 Sep 1;13(17):5056-62.
52. Lee YL, Kuo WH, Lin CW, Chen W, Cheng WE, Chen SC, et al. Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer. Lung Cancer 2011 Aug;73(2):147-52.
53. Teng YH, Liu TH, Tseng HC, Chung TT, Yeh CM, Li YC, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck 2009 Oct;31(10):1282-8.
54. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003 Jun 15;167(12):1676-86.
55. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005 Jun 10;280(23):22473-81.
56. Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs 2003 Feb;12(2):185-95.
57. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998 Dec 30;253(3):877-82.
58. Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg; 2012.
59. Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One 2011;6(9):e24856.
60. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008 Mar;15(3):504-14.
61. Gorelik E, Lokshin A, Levina V. Lung cancer stem cells as a target for therapy. Anticancer Agents Med Chem 2010 Feb;10(2):164-71.
62. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011 Jun;29(6):883-7.
63. Rivera C, Rivera S, Loriot Y, Vozenin MC, Deutsch E. Lung cancer stem cell: new insights on experimental models and preclinical data. J Oncol 2011;2011:549181.
64. Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, et al. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res 2010 Aug 15;70(16):6639-48.
65. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 2012.
66. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 2010 Jan 1;70(1):338-46.
67. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009 Sep 22;106(38):16281-6.
68. Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 2011 Jun 15;71(12):4236-46.
69. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011.
70. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 2012 Mar;21(3):341-53.
71. Balkwill FR. The chemokine system and cancer. J Pathol 2012 Jan;226(2):148-57.
72. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006 Mar 1;107(5):1761-7.
73. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009 Jan;23(1):43-52.
74. Otsuka S, Bebb G. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J Thorac Oncol 2008 Dec;3(12):1379-83.
75. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009 Jun 1;77(11):1655-64.
76. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009 Jun 4;113(23):5720-6.
77. DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat Rev Drug Discov 2009 Feb;8(2):105-6.
78. Beider K, Abraham M, Peled A. Chemokines and chemokine receptors in stem cell circulation. Front Biosci 2008;13:6820-33.
79. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood 2005 Sep 15;106:6:1901-10
80. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999 Feb 5;283(5403):845-8.
81. Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, et al. Development of a unique small molecule modulator of CXCR4. PLoS One 2012;7(4):e34038.